TSG is a wholly owned subsidiary of Ascendis Medical and supplies diagnostic laboratory equipment and consumables to pathology laboratories.
The partners will conduct an exploratory study to determine how the results of Exagen's lupus test impacts primary care physician practice referral patterns.
The funding will go toward expanding the firm's product line and increasing access to its testing services. MyLab Box has raised $2.1 million in total.
In May, Kurin sued Magnolia for allegedly making false claims about the efficacy and regulatory status of its Steripath blood culture collection system.
The planned joint venture with Beijing Zishan Health Consultancy is aimed at bringing Genetic Technologies' genomic tests to the Chinese market.
The Signatera research-use-only assay monitors cancer treatment and assesses minimal residual disease, and is customized for individual patients.
The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
The company has struck a deal to market its tests, including ones based on its Aristotle early cancer detection platform, in collaboration with LifeX.
The company's test volume during the quarter shrank to just over 1,000 samples compared to 1,405 in the same period last year.
The firm's overall growth in the quarter was led largely by 9 percent growth in its Diagnostics and Genomics Group.
The company had no Q2 revenues and continues to advance DetermaVu, its liquid biopsy lung cancer diagnostic test, toward commercialization.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
Research has found that antibodies to the marker HMGCR are highly specific to myositis and are associated with, but not limited to, statin exposure.
The test can be used on donated blood samples as well as other human cells and tissues.
The revenue increase was driven by surging direct sales of the firm's diagnostic test cartridges in Europe, the Middle East, and Asia.
The company is continuing to work with a financial advisor to evaluate strategic options, with discussions about potential transactions ongoing.
Siemens Healthineers received FDA clearances for several assays, including separate allowances for tests using hemoglobin A1c, troponin I, and procalcitonin biomarkers.
Lucence's test are designed to detect DNA fragments shed by a tumor into the blood and target the most common cancers in Asia such as lung cancer.
The battery-operated, hand-held device uses a broad-spectrum photometric method to provide accurate hemoglobin measurements in about one second.
The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.
Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.
The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.